⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INCY News
Incyte Genomics Inc
CMS(867.HK/8A8.SG):Ruxolitinib Phosphate Cream (Lumirix®) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo
globenewswire.com
INCY
CMS(867.HK/8A8.SG):Ruxolitinib Phosphate Cream (Lumirix®) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo
globenewswire.com
INCY
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight
prnewswire.com
GILD
INCY
BIIB
NVS
AMGN
JNJ
ABBV
BMY
AZN
MRK
PFE
TGTX
XNCR
CABA
IMUX
ZNTL
GLPG
CLNN
AUTL
Incyte annonce l’autorisation par la Commission européenne de Zynyz ® (rétifanlimab) pour le traitement de première intention du carcinome épidermoïde avancé du canal anal (SCAC)
businesswire.com
INCY
Incyte meldet die Zulassung von Zynyz ® (Retifanlimab) durch die Europäische Kommission für die Erstlinienbehandlung von fortgeschrittenem Plattenepithelkarzinom des Analkanals (Squamous Cell Carcinoma of the Anal Canal, SCAC)
businesswire.com
INCY
Incyte annuncia l'approvazione da parte della Commissione europea di Zynyz ® (retifanlimab) come terapia di prima linea del carcinoma anale a cellule squamose (SCAC) in fase avanzata
businesswire.com
INCY
Incyte kondigt goedkeuring van de Europese Commissie aan voor Zynyz ® (retifanlimab) voor de eerstelijnsbehandeling van gevorderd plaveiselcelcarcinoom van het anale kanaal (SCAC)
businesswire.com
INCY
Incyte anuncia que la Comisión Europea ha aprobado Zynyz ® (retifanlimab) para el tratamiento de primera línea del carcinoma de células escamosas del canal anal avanzado
businesswire.com
INCY
Form 8-K
sec.gov
INCY
Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
businesswire.com
INCY